Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study will assess and compare the safety and tolerability of inhaled TPI 1020 (repeated
nominal doses; 500 μg BID x 6 weeks) versus inhaled budesonide (repeated doses; 800 μg BID x
6 weeks) and a matching placebo. Pharmacodynamic (PD) activity on FEV1, sputum and blood
cells and cytokines will also be studied.